Drug Profile

Pevonedistat - Takeda Oncology

Alternative Names: MLN-4924; MLN4924-003; Pevonedistat hydrochloride; TAK 924

Latest Information Update: 27 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Millennium Pharmaceuticals
Developer Case Western Reserve University; Children's Oncology Group; Eli Lilly and Company; Greehey Childrens Cancer Research Institute; Louisiana State University; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Nationwide Children's Hospital; PETHEMA Foundation; Takeda Oncology; Translational Genomics Research Institute; University of Miami; University of Michigan Comprehensive Cancer Center; University of Southampton; University of Southern California; University of Texas M. D. Anderson Cancer Center; Vanderbilt-Ingram Cancer Center; Washington University School of Medicine
Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Antirheumatics; Cyclopentanes; Indenes; Pyrimidines; Pyrroles; Small molecules; Sulfonic acids
Mechanism of Action NEDD 8 activating enzyme inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Acute myeloid leukaemia; Myelodysplastic syndromes
New Molecular Entity Yes

Preclinical Rheumatoid arthritis
Discontinued Acute myeloid leukaemia; Cholangiocarcinoma; Chronic myelomonocytic leukaemia; Glioblastoma; Lymphoma; Mesothelioma; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders; Non-small cell lung cancer; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Renal cell carcinoma; Rhabdomyosarcoma; Solid tumours

25 Mar 2025 Takeda terminates a phase II trial for Acute myeloid leukaemia (Combination therapy, First-line therapy) in USA, Canada, France, Italy and Poland (NCT04266795)
14 Oct 2024 Takeda completes the phase III PANTHER trial in Acute myeloid leukaemia, Chronic myelomonocytic leukaemia and Myelodysplastic syndromes (Combination therapy, First-line therapy, In adults, In the elderly) in the US, Spain, Australia, Belgium, Brazil, Canada, China, Czech Republic, France, Germany, Greece, Israel, Italy, Japan, South Korea, Mexico, Poland, Russia, Turkey, United Kingdom (IV), (NCT03268954),
13 Jun 2024 Efficacy and adverse events data from a phase III trial in Acute myeloid leukemia presented at the 29th Congress of the European Haematology Association (EHA-2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com